For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Bicara Therapeutics Inc (NASDAQ: BCAX) closed the day trading at $16.71 up 0.60% from the previous closing price of $16.61. In other words, the price has increased by $0.60 from its previous closing price. On the day, 0.69 million shares were traded. BCAX stock price reached its highest trading level at $17.15 during the session, while it also had its lowest trading level at $16.455.
Ratios:
For a better understanding of BCAX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 25.80 and its Current Ratio is at 25.80. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $36.
On May 23, 2025, Wells Fargo Upgraded its rating to Equal Weight which previously was Underweight but kept the price unchanged to $8.
On April 17, 2025, Wells Fargo started tracking the stock assigning a Underweight rating and target price of $8.Wells Fargo initiated its Underweight rating on April 17, 2025, with a $8 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 29 ’25 when Meisner Lara sold 33,807 shares for $14.75 per share. The transaction valued at 498,653 led to the insider holds 0 shares of the business.
LARA MEISNER bought 33,807 shares of BCAX for $395,880 on Sep 29 ’25. On Sep 15 ’25, another insider, Meisner Lara, who serves as the Chief Legal Officer of the company, sold 15,829 shares for $11.49 each. As a result, the insider received 181,875 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCAX now has a Market Capitalization of 911745024 and an Enterprise Value of 477377088.
Stock Price History:
The Beta on a monthly basis for BCAX is -0.82, which has changed by -0.33585054 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, BCAX has reached a high of $28.09, while it has fallen to a 52-week low of $7.80. The 50-Day Moving Average of the stock is 42.52%, while the 200-Day Moving Average is calculated to be 33.75%.
Shares Statistics:
Over the past 3-months, BCAX traded about 383.35K shares per day on average, while over the past 10 days, BCAX traded about 835230 shares per day. A total of 54.56M shares are outstanding, with a floating share count of 30.93M. Insiders hold about 43.30% of the company’s shares, while institutions hold 64.11% stake in the company. Shares short for BCAX as of 1757894400 were 5669220 with a Short Ratio of 14.79, compared to 1755216000 on 5460303. Therefore, it implies a Short% of Shares Outstanding of 5669220 and a Short% of Float of 16.259999999999998.
Earnings Estimates
The market rating for Bicara Therapeutics Inc (BCAX) is a result of the insights provided by 8.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.37 and low estimates of -$0.69.
Analysts are recommending an EPS of between -$1.91 and -$2.43 for the fiscal current year, implying an average EPS of -$2.22. EPS for the following year is -$2.45, with 8.0 analysts recommending between -$1.88 and -$3.01.
